Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821066 | 0.83 | KDM4E (0.41) | L3MBTL1ALDH1A1KDM4ESMN1; SMN2PDK1 | |
| SCHEMBL2601270 | 0.81 | NPC1 (0.52) | L3MBTL1ALDH1A1KDM4EPOLBNPC1 | |
| SCHEMBL2494002 | 0.81 | RAB9A (0.59) | L3MBTL1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL374899 | 0.81 | KMT2A (0.46) | L3MBTL1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL8613491 | 0.80 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29431831 | 0.80 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL510235 | 0.80 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28729464 | 0.80 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL623831 | 0.80 | METAP1 (0.46) | NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL29476654 | 0.80 | METAP1 (0.46) | NPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066322-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4337650-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117279906-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114262293-B | Preparation method of 2-amino-3-bromopyridine | 上海有吉医药化工有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2022241173-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| CN-114262293-A | Preparation method of 2-amino-3-bromopyridine | 安徽有吉医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| WO-2019049061-A1 | 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019049061-A1 | 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-14 | — | — | WO | disclosed |
| WO-2014121055-A2 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20060041144-A1 | Phenylpyridine compound and fungicidal compostion containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
| EP-1541557-A1 | PHENYLPYRIDINE COMPOUND AND BACTERICIDAL COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0963986-B1 | 5,10-Dihydrodipyrido(2,3-b:2,3-e)pyrazine and 5,10-dihydro(2,3-b:3,2-e)pyrazine, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-04-17 | — | — | EP | disclosed |
| EP-0963986-A2 | 5,10-Dihydrodipyrido(2,3-b:2,3-e)pyrazine and 5,10-dihydro(2,3-b:3,2-e)pyrazine, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | L3MBTL1 3557/4885ALDH1A1 317/4885CYP1A2 226/4885 |
| US-20060041144-A1 | Phenylpyridine compound and fungicidal compostion containing the same | CBR3, CYP1A1, PAH | L3MBTL1 222/4885ALDH1A1 2020/4885CYP1A2 20/4885 |
| US-20250066322-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, STAT3, JAK2 | L3MBTL1 4081/4885ALDH1A1 3387/4885CYP1A2 1584/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | L3MBTL1 2907/4885ALDH1A1 427/4885CYP1A2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.